Mymetics Corp (MYMX)

[Work Harder]

Matthijs Baart is currently affiliated with Mymetics BV, Leiden, TheNetherlands

All authors were affiliated to Crucell Vaccine Institute, Janssen Center ofExcellence for Immunoprophylaxis, Crucell Holland BV, Leiden, The Netherlands,during the time they contributed to the work presented in this thesis except thefollowing:• Stephen Kent,- Department of Microbiology and Immunology at the Peter DohertyInstitute for Infection and Immunity, The University of Melbourne, Parkville,Victoria 3010, Australia- Melbourne Sexual Health Center, Central Clinical School, MonashUniversity, Melbourne, Australia

https://translate.google.com/translate?hl=en&sl=nl&u=https://pure.uva.nl/ws/files/2728908/174219_08_1_.pdf&prev=search&pto=aue

From that

In this thesis, we explore whether the protective efficacy of a trivalent virosomal seasonal influenza vaccine (TVV) can be broadened and thereby increase pandemic preparedness until more broadly protective influenza vaccines may become available.

https://translate.google.com/translate?hl=en&sl=nl&u=https://pure.uva.nl/ws/files/2728908/174219_08_1_.pdf&prev=search&pto=aue

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157822100

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157821804

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157820920

https://wyss.harvard.edu/news/putting-a-crown-on-omnivax/

liposomes or virosomes,

https://patents.justia.com/inventor/david-j-mooney?page=2

https://mooneylab.seas.harvard.edu/

https://www.google.com/maps/dir/Mymetics+B.V.,+J.H.+Oortweg,+Leiden,+Netherlands/Batavia+Biosciences+B.V.,+Zernikedreef+16,+2333+CL+Leiden,+Netherlands/@52.1680097,4.4638038,17z/data=!3m1!4b1!4m13!4m12!1m5!1m1!1s0x47c5c71fc37b7e4b:0xae33d5031fcd8249!2m2!1d4.4652569!2d52.16894!1m5!1m1!1s0x47c5c6e108852819:0x92661631a5eeb8f3!2m2!1d4.4667178!2d52.1667448